Abstract 168P
Background
China accounts for half of new esophageal cancer (EC) cases in the world. Limited new therapies were developed during the past decades until the advent of immuno-oncology (IO) in 2020. Yet real-world data is scarce for Chinese EC patients prior to IO approval. This nationwide multicenter retrospective study aimed to describe clinical features and treatment patterns of EC in China to capture baseline treatment landscape as the benchmark before IO approval.
Methods
Patient-level data of patients who initiated first therapy for newly diagnosed EC in 2018 were extracted from a large nationwide database. Information within 6 months after initial anti-tumor treatment were obtained and descriptively summarized.
Results
A total of 3493 EC patients from 14 hospitals in China were included in this study, with mean age of 64.1 years at initial diagnosis. The majority of patients were male (75.7%), squamous cell carcinoma (92.8%), with primary lesion at middle (56.4%) esophagus and living in urban area (53.4%). The proportion of stage I, II and III and IV was 14.9%, 31.6%, 39.2%,14.2%, respectively. Out of the 2138 resectable patients, 1986 underwent upfront radical surgery, while 7.1% patients received neoadjuvant therapy, among which chemotherapy was mainstay preoperative therapy (85.5%). Twenty-three percent of resectable patients had adjuvant therapy, with chemotherapy as the mainstream (75.2%) postoperative regimen. For unresectable early and locally advanced patients, the percentage of radical therapy and palliative therapy was 49.9% and 50.1%, respectively, and definitive chemoradiotherapy was the most common treatment (32.0%). For advanced stage patients, chemotherapy accounted for 84.3% of upfront therapy and taxane-based chemotherapy regimen predominated (66.2%).
Conclusions
In this large observational study, most early-stage and locally advanced patients underwent upfront surgery without preoperative treatment, while for advanced patients, chemotherapy was the primary choice. This is the first real-world study of EC to date with largest sample size reflecting Chinese treatment landscape before IO approval, which will help address unmet needs in clinical practice.
Clinical trial identification
EU PAS Register Number: EUPAS48396, release on 29/07/2022.
Editorial acknowledgement
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. MSD China holding.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure
D.F. Shi, Q. Jing, S. Shi, F. Dong: Financial Interests, Personal, Full or part-time Employment: MSD China. All other authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract